SMA News Forums › Forums › Flash Briefings and Podcasts › Risdiplam Under FDA Review & How the Lack of SMA Protein May Also Directly Contribute to SMA

  • Flash Briefings and Podcasts

    Risdiplam Under FDA Review & How the Lack of SMA Protein May Also Directly Contribute to SMA

    Posted by sma-news-today-moderator on March 16, 2020 at 11:05 am

    Anticipation is growing as Roche/Genentech’s treatment risdiplam, the first oral medication to treat SMA, is under FDA review.

    Also, SMA News Today’s multimedia associate, Price Wooldridge, discusses how the lack of SMA protein may also directly contribute to SMA.

    Are you interested in learning more about spinal muscular atrophy? If so, please visit smanewstoday.com/

    What are your thoughts on this news? Let us know about it in the comment section below.
    sma-news-today-moderator replied 3 years, 2 months ago 0 Member · 0 Replies
  • 0 Replies

Sorry, there were no replies found.

Start of Discussion
0 of 0 replies June 2018
Now

Report

Harassment or bullying behavior
Contains mature or sensitive content
Contains misleading or false information
Contains abusive or derogatory content
Contains spam, fake content or potential malware

Block Member?

Please confirm you want to block this member.

You will no longer be able to:

  • See blocked member's posts
  • Mention this member in posts
  • Invite this member to groups
  • Message this member
  • Add this member as a connection

Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.

Report

You have already reported this .